Warning Letter due to Non-Compliance with Specifications
Recommendation
Tuesday, 4 February 2025 9 .00 - 17.00 h
Establishment, Use and Maintenance of Analytical Reference Substances
This FDA Warning Letter issued to Chinese pharmaceutical manufacturer Shanwei Honghui Daily Appliance Co. Ltd. in China from 05 December, 2017, is based on an FDA inspection from July/August 2017.
The company failed to check all batches of the manufactured drug product for compliance with the specifications.
It became apparent during the inspection that incoming active pharmaceutical ingredients and excipients were not tested for identity upon entry. The company instead relied on the supplier's certificates of analysis. However, those had not been qualified.
Shanwei Honghui had not verified the analysis results from the supplier's certificates. There was no adequate validation in the form of checking the supplier's analysis results in regular intervals.
In their response to the FDA on 23 August, 2017, Shanwei Honghui named a lack of experience with the FDA as a reason for this. The response is described as inadequate and not detailed enough in the FDA warning letter.
As a consequence, the FDA now placed the company on Import Alert.
Further details are available in the complete FDA Warning Letter issued to Shanwei Honghui Daily Appliance Co. Ltd.
Related GMP News
16.10.2024US FDA Warning Letter: Lab Data Integrity issues
16.10.2024FDA Warning Letter: Component Testing, Validation, and Stability
16.10.2024EDQM publishes New Chapter "Quality of Data" for Comments
16.10.2024USP Chapter <621> Chromatography: Notice of Intent to Revise
15.10.2024Pharmeuropa Text for Comment: HPTLC for Herbal Products
09.10.2024WHO Biowaiver Project Cycle VII (2025) and Results from Cycle VI (2024)